[78]
Abbott bases its position on what it calls a "discrete error." Abbott says that Prothonotary Milczynski first concluded that there was "no evidence" substantiating Novopharm's assertions that everything in the relevant documents and information was confidential, and then went on to protect certain documents and information notwithstanding this purported lack of evidence.